BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961 [PMID: 37731995 DOI: 10.3748/wjg.v29.i33.4942]
URL: https://www.wjgnet.com/1007-9327/full/v29/i33/4942.htm
Number Citing Articles
1
Arzu Altunçekiç Yıldırım, Celali Kurt, Burcu Ülküden, Yeliz Çetinkol. Hepatitis B Virus Reactivation with Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature ReviewViral Hepatitis Journal 2024; 30(1): 19 doi: 10.4274/vhd.galenos.2024.2024-1-1
2
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategiesWorld Journal of Gastroenterology 2024; 30(10): 1295-1312 doi: 10.3748/wjg.v30.i10.1295
3
Sergey Morozov, Sergey Batskikh. Reactivation of hepatitis B virus infection – an important aspect of multifaceted problemWorld Journal of Gastroenterology 2024; 30(26): 3193-3197 doi: 10.3748/wjg.v30.i26.3193
4
Michele Barone. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatmentsWorld Journal of Gastroenterology 2024; 30(25): 3147-3151 doi: 10.3748/wjg.v30.i25.3147
5
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita. Current perspectives of viral hepatitisWorld Journal of Gastroenterology 2024; 30(18): 2402-2417 doi: 10.3748/wjg.v30.i18.2402
6
Jata Shankar Kumar, Deepanshu Khanna, Premashish Kar. Approach to diagnosis and management of reactivation of chronic hepatitis BFuture Virology 2024; 19(6-7): 273 doi: 10.1080/17460794.2024.2356427
7
Abdullah S. Shaikh, Susan C. Abraham, Lan S. Wang, Harrys A. Torres, Hao Chi Zhang. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to AcalabrutinibACG Case Reports Journal 2024; 11(6): e01387 doi: 10.14309/crj.0000000000001387
8
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, Roberta Murru, Roberto Marasca. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted AgentsCancers 2024; 16(11): 1996 doi: 10.3390/cancers16111996
9
Bansi P Savaliya, Ramin Shekouhi, Fatima Mubarak, Harsheen K Manaise, Paola Berrios Jimenez, Gabrielle Kowkabany, Reed A Popp, Kyle Popp, Emmanuel Gabriel. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitorsWorld Journal of Gastroenterology 2024; 30(24): 3052-3058 doi: 10.3748/wjg.v30.i24.3052
10
Matteo Tonnini, Clara Solera Horna, Luca Ielasi. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?World Journal of Gastroenterology 2024; 30(5): 509-511 doi: 10.3748/wjg.v30.i5.509
11
Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola. Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysisWorld Journal of Gastroenterology 2024; 30(9): 1253-1256 doi: 10.3748/wjg.v30.i9.1253
12
Wei-Nung Liu, Ming-Shen Dai, Felicia Lin, Gen-Min Lin. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitorsWorld Journal of Gastroenterology 2024; 30(21): 2748-2750 doi: 10.3748/wjg.v30.i21.2748